Evonik Operations Gmbh

Degussa Aktiengesellschaft

Other

Forschungszentrum Juelich Gmbh

Evonik Degussa Gmbh

Guenter Knaup

Karlheinz Drauz

Michael Schwarm

Gerard Richet

Thomas Gottstein

Werner Kleophas

Adolf Gruenert

Christian Wandrey

Andreas Bommarius

Matthias Kottenhahn

Meir Lahav

Milan Latinovic

Friedhelm Merz

Joerg Lotz

Alexander Schwarz

David Zbaida

Karl-Heinz Drauz

Andreas Fischer

The present invention relates to a tablet comprising one or more omega-3 fatty acid amino acid salt(s), a method for preparing a tablet according to the invention and the use of a tablet according to the invention as a food supplement or as a pharmaceutical product.

Tablets with high active ingredient content of omega-3 fatty acid amino acid salts

The present invention relates to a tablet comprising one or more omega-3 fatty acid amino acid salts, a method for preparing a tablet according to the invention and the use of a tablet according to the invention as a food supplement or as a pharmaceutical product.

Disclosed herein is a cell culture media containing L-glutamine from a set of N-acylated dipeptides Acyl-X-Q, and L-glutamine from a set of other glutamine-sources Qsource in a defined molar ratio R=n(Acyl-X-Q)/n(Qsource), wherein the variables X, Q, Acyl, R, n(Acyl-X-Q) and n(Qsource) are defined in the general disclosure. Processes of using the cell culture media are also described herein.

Culture media comprising n-Acyl-X-glutamine dipeptides

The present invention relates to a method for preparing a composition comprising one or more omega-3 fatty acid salt(s), the composition obtainable or obtained by this method, and also the use of this composition for the preparation of foodstuffs, food supplements or pharmaceutical products.

Method for preparing a composition comprising omega-3 fatty acid salts and amines

The invention relates to a special amino acid mixture for hemodialysis as well as to the dialysis solution that can be prepared from the amino acid mixture. When the amino acid mixtures according to the invention are used for such purposes, the &ldquo;shrinking men&rdquo; phenomenon cam be prevented. The present invention also relates to a hemodialysis process and apparatus. This aspect of the invention provides a closed dialysis system with a dialyzer solution containing the amino acid mixtures according to the invention.

Amino acid composition for hemodialysis

The invention relates to a special amino acid mixture for hemodialysis as well as to the dialysis solution that can be prepared from the amino acid mixture. When the amino acid mixtures according to the invention are used for such purposes, the &ldquo;shrinking men&rdquo; phenomenon can be prevented. The present invention also relates to a hemodialysis process and apparatus. This aspect of the invention provides a closed dialysis system with a dialyzer solution containing the amino acid mixtures according to the invention.

The present invention relates to a process for the resolution of DL-racemic mixtures of compounds which crystalize in the form of a conglumerate. Both, the D and L-enantiomers are obtained according to the invention in a industrially feasable process by adding chiral enantioselective polymers to the supersaturated solution of the racemat to inhibit crystalization of one enantiomer. Next a DL-racemic mixture of said compound is suspended in about twice the amount of the crystallized enantiomer. Consequently, the opposite enantiomer could be recovered by said suspension by physical separation.

Resolution of DL-racemic mixtures

Protected and unprotected di- or oligopeptides are synthesized by reacting an N-terminally protected .alpha.-amino acid alkyl ester or peptide alkyl ester of the formula X--E--R.sup.1 with an amino acid or a di- or oligopeptide or a derivative thereof of the formula H.sub.2 N--Q--R.sup.2 in aqueous solution in the presence of a hydrolase, and, removing protective groups from the reaction product separated from the reaction mixture, where E is the residue of an .alpha.-amino acid or of a di- or oligopeptide, R.sup.1 is lower alkyl and X is a group which carries a charge or is polar at the pH values used for the reaction and which increases the solubility by a factor &gt;5 compared with compounds wherein X=H, Q is the residue of an amino acid or of a di- or oligopeptide, and R.sup.2 is an optionally esterified or amidated acid group. In a preferred embodiment, the peptide or (.alpha.-)amino acid ester concentration is greater than 50 mM, wherein in a particularly preferred embodiment, the concentration ranges from 100 to 1000 mM with approximately comparable nucleophile and electrophile concentrations. The preferred substrate/enzyme ratios are &gt;10.sup.5 M/M or &gt;10.sup.3 M/M when papain is employed. Phthalyl, maleyl or citraconyl radicals and their derivatives or N-betainyl compounds are envisaged for use radicals (X) in the electrophilic component.

Growing community of inventors

Bruchkoebel, Germany

Guenter Knaup